Genetic diagnostics firm GeneDx posted a 49% year-over-year revenue increase in Q2 2025 to $102.7 million, fueled primarily by a 69% surge in whole-exome and whole-genome testing revenues, which comprised 84% of total income. The company performed 23,102 such tests in the quarter, up 28% over the prior year. Despite declines in hereditary cancer testing, GeneDx achieved profitability for the fourth consecutive quarter, with net income rising to $10.8 million. Efforts to improve reimbursement and expand into the general pediatrics market underpin the firm’s positive outlook.